theinvestor22 wrote: Reasons not to invest in RHT.
You think:
- The software doesn't meet a recognized need
- The software doesn't work as specified
- CMS doesn't fund the services supported by the Reliq's offerings
- Virtually all of Reliq's clients (about 170 of them since late May 2019) have not done sufficient due diligence before executing contracts and implementation plans
- The company's pre-screening is ineffective
- Covid has not affected onboarding as stated by the company
- Patients will not use the system or will not use it regularly enough for it to be fundable
- The company did not extend payment terms with clients during the initial stages of covid
- The auditor is incompetent
- Notwithstanding the collection of accounts receivable which started in FQ2, the company will not be able to collect significant amounts going forward
- The company's partnership with Cognizant will not result in any larger deals being executed
- The company will not be able to sign any larger deals on its own
- The company's share price based on a discounted future cash flow model is too high
Now, I happen to think that just one medium sized deal with partner Cognizant - without any contribution from anything else - would be enough to get the company onto the NASDAQ, but that's just me. As for the other 170ish deals, well, they might add a little something, yes?